

Self-Assembling Multidomain Peptide Nanofibers for Delivery of Bioactive Molecules and Tissue Regeneration

Amanda N. Moore and Jeffrey D. Hartgerink

Department of Chemistry and Bioengineering, Rice University, 6500 Main Street, Houston, Texas 77005, United States

SI Table 1. Published Multidomain Peptide Sequences

<i>Peptide Sequence</i>	<i>Reference</i>	<i>Designed Bioactivity</i>
(QL) ₆	11	N/A
K(QL) ₆ K	11	N/A
K ₂ (QL) ₂ K ₂	11	N/A
K ₂ (QL) ₃ K ₂	11	N/A
K ₂ (QL) ₄ K ₂	11	N/A
K ₂ (QL) ₅ K ₂	11	N/A
K ₂ (QL) ₆ K ₂	11, 12, 21, 14	N/A
K ₃ (QL) ₆ K ₃	11	N/A
K ₄ (QL) ₆ K ₄	11	N/A
K ₂ (QF) ₆ K ₂	14	N/A
K ₂ (QFQL) ₃ K ₂	14	N/A
K ₂ (QW) ₆ K ₂	14	N/A
K ₂ (QY) ₆ K ₂	14	N/A
K ₂ (SL) ₆ K ₂	12, 13, 16, 21, 23, 29, 31	N/A
K ₂ (TL) ₆ K ₂	13	N/A
E(QL) ₆ E	12	N/A
E(SL) ₆ E	12	N/A
E ₂ (SL) ₆ E ₂	21	N/A
E(CL ₃ SL) ₃ E	12	N/A
K ₂ (SL) ₂ SA(SL) ₃ K ₂	29	N/A
K ₂ (SL) ₂ (SA) ₂ (SL) ₂ K ₂	29	N/A
E ₂ (SL) ₆ E ₂ GRGDS	17, 27	cell adhesion
K(SL) ₃ RG(SL) ₃ KGRGDS	13, 16, 19, 20, 23, 24, 25, 26, 28, 31	cell adhesion & enzymatic degradation
K(TL) ₂ SLRG(TL) ₃ KGRGDS	13	cell adhesion & enzymatic degradation
K ₂ (SL) ₆ K ₂ GRGDS	13, 16	cell adhesion
K ₂ (TL) ₆ K ₂ GRGDS	13	cell adhesion
K(SL) ₃ RG(SL) ₃ K	16, 30,31	enzymatic degradation
K ₂ (SL) ₃ RG(SL) ₃ K ₂	16	enzymatic degradation
K(SL) ₃ RG(SL) ₃ KGKLTWQELYQLKYKGI	30, 31	enzymatic degradation & angiogenesis

SI Table 2. Cell and Tissue Culture using Multidomain Peptides

<i>Cell Type Used</i>	<i>Peptide(s) examined</i>	<i>Culture system</i>	<i>Reference</i>
SHED	K ₂ (SL) ₆ K ₂	2D/3D	13, 16
	K ₂ (SL) ₆ K ₂ GRGDS		
	K(SL) ₃ RG(SL) ₃ K		
	K(SL) ₃ RG(SL) ₃ KGRGDS		
	K ₂ (TL) ₆ K ₂		
DPSC	K ₂ (TL) ₆ K ₂ GRGDS	2D/3D	25
	K(TL) ₂ SLRG(TL) ₃ KGRGDS		
	K(SL) ₃ RG(SL) ₃ KGRGDS		
hMSCs	K ₂ (SL) ₆ K ₂	2D	31
	K(SL) ₃ RG(SL) ₃ KGRGDS		
HUVEC	K(SL) ₃ RG(SL) ₃ KGKLTWQELYQLKYKGI	2D	30, 31
	K(SL) ₃ RG(SL) ₃ KGRGDS		
THP-1	K(SL) ₃ RG(SL) ₃ KGKLTWQELYQLKYKGI	2D	19, 23
	K ₂ (SL) ₆ K ₂		
<i>Ex vivo</i> mandible slice	K(SL) ₃ RG(SL) ₃ KGRGDS	organ culture	20
Whole blood	K(SL) ₃ RG(SL) ₃ KGRGDS	blood clotting model	26

SI Table 3. *In Vivo* Studies of Multidomain Peptides

<i>Model</i>	<i>Peptide(s) examined</i>	<i>Reference(s)</i>
Subcutaneous injection	K(SL) ₃ RG(SL) ₃ KGRGDS	19, 23, 28, 31
	K(SL) ₃ RG(SL) ₃ K	
Hind Limb Ischemia	K(SL) ₃ RG(SL) ₃ K	30
	K(SL) ₃ RG(SL) ₃ KGKLTWQELYQLKYKGI	
Perioperative bleeding: Liver Incision	K(SL) ₃ RG(SL) ₃ KGRGDS	26

SI Table 4. Delivery of Bioactive Molecules using Multidomain Peptides

<i>Molecule</i>	<i>Reference</i>
hESC secretome	17
Suramin	19
MCP-1	23, 24
IL-4	23
EGF	24
PlGF-1	24, 28
TGF β 1	25
FGF2	25
VEGF	25
Batroxobin	26
SN-38	29
Diflunisal	29
Etodolac	29
Daunorubicin	29
Levofloxacin	29
Norfloxacin	29
VEGF	31

All reference numbers refer to citations in the main text.